Equal-Weight Strategy RSP Could Outrun SPY if This Macro Shift Continues

RSP’s relative strength is less about “equal weight” as a style and more about a regime bet on lower front-end rates and a steeper curve. If the Fed eases into a still-intact economy, the index’s mix of cyclical, levered, and mean-reversion names should benefit from both multiple expansion and earnings leverage, while the mega-cap growth complex loses its scarcity premium. The first-order winner is broad beta outside the largest growth franchises; the second-order winner is any company whose stock has lagged enough to force mechanical rebuying at rebalance.

The rebalance is the cleaner near-term catalyst because it is flow-driven and predictable. Names that have outpaced their target weights will face forced selling regardless of fundamentals, which can create a short-lived air pocket in the semis and other winners, while laggards get an automatic bid. That flow matters most over days to a few weeks; the macro curve trade matters over 1-3 months; the durable relative-performance case depends on whether cuts arrive without a growth scare. If cuts are driven by recession, RSP’s cyclicals and transport/financial exposure become a trap rather than a tailwind.

The consensus may be overreading “broadening” as a structural equity bull signal. A lot of the recent outperformance can simply be arithmetic: prior excess concentration in a handful of winners is mean-reverting. That argues for a tactical posture, not a strategic all-in. The thesis is falsified if the 10Y-2Y spread slips back toward inversion or if Fed pricing removes the cut path; in that scenario, cap-weighted growth leadership should reassert quickly and the equal-weight premium should fade.